News

Video

Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma

Author(s):

Kami J. Maddocks, MDAlexey V. Danilov, MD, PhD

Experts discuss data on pirtobrutinib, a non-covalent BTK inhibitor, in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Related Videos
Tycel Phillips, MD, MPH
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Related Content
Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Lori A. Leslie, MD
February 27th 2023

FDA Approval Insights: Pirtobrutinib in MCL

MCL | Image Credit: ©freshidea - stock.adobe.com
May 20th 2024

Adding Ibrutinib to Chemoimmunotherapy Induction Improves FFS in Younger MCL

Joshua Brody, MD
December 8th 2022

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

Jean L. Koff, MD, MS, Winship Cancer Institute
May 13th 2024

Efficacy and Safety of Pirtobrutinib Continue to Reshape MCL Treatment Paradigm

Michael Wang, MD
May 2nd 2024

Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL